Solid dispersions containing kinase inhibitors
First Claim
1. A solid dispersion product comprising N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno [3,2-c]pyridin-3-yl}phenyl)-N′
- -(3-fluorophenyl)urea or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable water-soluble polymeric carrier, and at least one pharmaceutically acceptable surfactant, wherein the N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′
-(3-fluorophenyl)urea is present in about 1% to about 40% by free base equivalent weight.
2 Assignments
0 Petitions
Accused Products
Abstract
A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.
-
Citations
16 Claims
-
1. A solid dispersion product comprising N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno [3,2-c]pyridin-3-yl}phenyl)-N′
- -(3-fluorophenyl)urea or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable water-soluble polymeric carrier, and at least one pharmaceutically acceptable surfactant, wherein the N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′
-(3-fluorophenyl)urea is present in about 1% to about 40% by free base equivalent weight. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
- -(3-fluorophenyl)urea or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable water-soluble polymeric carrier, and at least one pharmaceutically acceptable surfactant, wherein the N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′
Specification